Clinical Trial Supplies Market: Current Analysis and Forecast (2022-2028)

The clinical trial supplies market is a segment of the pharmaceutical and biotechnology industry that provides a wide range of products and services necessary for the conduct of clinical trials. These products and services include, but are not limited to, laboratory equipment, medical devices, pharmaceuticals, and biological samples. The clinical trial supplies market is a rapidly growing industry, driven by the increasing demand for new and innovative treatments for various diseases and conditions. The market is also influenced by advances in technology, which have made it easier and more efficient to conduct clinical trials.

The Clinical Trial Supplies Market is expected to grow at a strong CAGR of 7% during the forecast period owing to the surge in the demand for biologics drugs. The number of biologics and temperature-sensitive drugs in clinical trials has seen a significant increase. Currently, 38.0% of pharmaceutical drugs and 35.0% of late-phase pharmaceutical drugs are biologics, and this number is expected to grow in the future due to the decreased adverse effects compared to traditional treatments for temperature-sensitive drugs. This rise in the number of biologics in clinical trials is expected to drive the demand for cold chain facilities. It is estimated that by 2022, 8 out of the top 10 biopharmaceutical products will require cold chain facilities, and the growing demand for biosimilars in both developing and developed economies will further boost the cold chain supply, contributing to the growth of the market over the forecast period.

Based on the phase, the market is segmented into phase-I, phase-II, phase-III, and phase-IV. The phase-I is anticipated to witness high CAGR during the forecast period. The COVID-19 pandemic has led to a significant increase in the number of clinical trials for its treatment and prevention, particularly in the phase I trials. For instance, in March 2021, Pfizer Inc. initiated phase-I clinical trial to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for SARS-CoV-2, the virus that causes COVID-19.

By services, the market is categorized in manufacturing, storage & distribution, supply chain management, and comparator sourcing. The supply chain management held a significant share of the market in 2021. The supply chain management segment is a critical component of the clinical trial supplies market, as it plays a key role in ensuring the success of clinical trials. The efficient management of supplies and materials is essential to ensure that clinical trials are conducted in a timely and cost-effective manner, and that the safety and well-being of trial participants are protected.

Based on end use, the market is categorized into pharmaceutical, biologics, medical device, and others. The biologics category is anticipated to grow with a significant CAGR during the forecast period. In recent years, the use of biologics such as hormones, blood products, vaccines, genes, insulin, and monoclonal antibody (mAb) products has increased as advanced therapies for the treatment of diseases like Crohn's disease, rheumatoid arthritis, and other autoimmune diseases. The increased widespread use has led to significant growth in the biologics market over the forecast period. The rapid increase in the number of cancer cases is also driving the growth of the biologics market. Biologics therapy is becoming increasingly popular as it uses the body's immune systems and abilities to fight cancer or heal healthy tissue after treatment. For instance, the Journal of Global Oncology reported that biologics accounted for an overall 55% of the total expenditure on antineoplastic drugs in the healthcare system. As a result, the higher incidence of cancer cases is expected to drive the growth of the biologics market.

Based on therapeutic use, the market is categorized into oncology, CNS, cardiovascular, infectious disease, metabolic disorders, dermatology, ophthalmology, and others. The oncology segment held a dominant share of the market in 2021. The oncology segment has a large and active R&D pipeline, with many new drugs and treatments in development. This pipeline includes a wide range of therapies, including targeted therapies, immunotherapies, and others. The development of new drugs and treatments is expected to drive the growth of the oncology segment in the clinical trial supplies market.

For a better understanding of the market adoption of the clinical trial supplies industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held the dominant share of the market and is expected to do so even in the forecast period. North America clinical trial supplies market is driven by a number of factors, including the high number of clinical trials being conducted in the region, the increasing demand for new and innovative treatments, and the presence of a large number of pharmaceutical and biotechnology companies. According to the Center for Information and Statistics on Clinical Research, there were over 59,000 clinical trials registered in the US in 2020. Further, North America is home to the largest number of projects in Phase 2 trials in 2020, which has resulted in significant investments in R&D by both industry and non-industry sponsors. For instance, in the clinical trials logistics survey conducted in 2021, it was found that approximately 60% of Phase 2 trials are outsourced. This is due to the high concentration of pharmaceutical leaders in the region, which has driven the development of innovative combinations of approved and novel treatments, resulting in a higher number of Phase 2 trial studies.

Some of the major players operating in the market include: Thermo Fisher Scientific; Catalent, Inc.; Parexel; Almac Group; Marken; Piramal Pharma Solutions; Inizio; Recipharm; Myonex; Rubicon Research Pvt. Ltd..